25-368 Phase I
A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations
AlertThis hospital website will retire on August 18th. To better serve Mass General Brigham patients, we are consolidating all hospital websites into one system website. After August 18th, you will be able to find information about all our services, physicians, and locations on massgeneralbrigham.org.
A Phase 1/1b Study of IAM1363 in Participants with Advanced Cancers Harboring HER2 Alterations
A phase 2 randomized open-label pilot study of Granulocyte Colony Stimulating Factor (G-CSF) to preserve brain structure and function following standard chemoradiation in patients with newly diagnosed MGMT-methylated glioblastoma
A Phase 2 Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Silevertinib, an Oral EGFR Inhibitor, in Combination with Temozolomide in Patients with Newly Diagnosed Glioblastoma with Unmethylated MGMT Promoter and EGFRvIII
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children with Average-Risk Medulloblastoma and Reduced Therapy in Children with Medulloblastoma with Low-Risk Features
A Phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1 (IDH1)-mutant glioma
A Phase I, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination with Radiation Therapy in Patients with Glioblastoma Multiforme and Brain Metastases from Solid Tumors
A Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study of HM16390 in Patients with Advanced or Metastatic Solid Tumors
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
A071401: Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Mutations
ACNS2321: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas